Sector Chart Oramed Pharmaceuticals Inc. Deutsche Boerse AG
Stocks
OJU1
US68403P2039
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
02:02:26 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 4.280 EUR | -0.81% |
|
+5.42% | +77.45% |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
| 08-10 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 50.47B | |||||
| 44.56B | - | - | - | - | - |
| 43.08B | |||||
| 41.7B | |||||
| 33.21B |
Select your edition
All financial news and data tailored to specific country editions
